Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Prescribing-center vial orders reached 950, compared with 926 in the fiscal third quarter, alongside higher wholesaler purchases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Citius Oncology (Nasdaq: CTOR) reported preliminary LYMPHIR unit sales to U.S. wholesalers rose 120% in its fiscal fourth quarter.
Wholesalers purchased 792 units in the three months ended September 30, 2026, versus 360 in the preceding quarter. Prescribing centers ordered 950 vials from wholesalers, compared with 926 in the fiscal third quarter. By October 26, 54 institutions had ordered LYMPHIR, versus 44 as of August 14. The company targets formulary placement at 100 priority institutions by calendar year-end and expects continued sales growth in fiscal 2027.
The figures are preliminary and unaudited, pending year-end closing and audit. Revenue reflects fulfilled wholesaler orders, net of estimated adjustments, rather than institutional vial orders. Complete quarterly and fiscal 2026 results are expected in December 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointWholesaler unit sales rose 120% to 792 in fiscal Q4 2026, versus 360 in fiscal Q3.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Fiscal 2027 sales growth expected by Citius Oncology, alongside growing institutional demand and deeper treatment-center penetration.
- Minor pointPrescribing-center orders increased to 950 vials in fiscal Q4, versus 926 in fiscal Q3.
- Minor point54 institutions had ordered LYMPHIR by October 26, versus 44 as of August 14, 2026.
- Minor pointExpanded commercial team reached nationwide coverage in August 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.100 priority institutions targeted for LYMPHIR formulary placement by calendar year-end.
Negative
- Minor pointPreliminary, unaudited unit figures remain subject to year-end closing procedures and the fiscal 2026 audit.
Details
Market Reaction – CTOR
On Oct 26, the day this news came out, the latest delayed price for CTOR is 11.44% above the previous close. Argus tracked a peak move of +10.4% during the session. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $0.65. Relative volume is very high at 3.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Wholesaler units
- 792 units vs. 360 units; increase of 120%
- Fiscal Q4 2026 vs. fiscal Q3 2026
- Institutional vial orders
- 950 vials vs. 926 vials
- Fiscal Q4 2026 vs. fiscal Q3 2026
- Institutions ordering LYMPHIR
- 54 institutions vs. 44 institutions
- As of the release date vs. August 14, 2026
Historical Context
-
Reported 926 LYMPHIR vial orders and 44 institutions, establishing the prior-quarter demand baseline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers more than doubled as our expanded commercial team reached nationwide coverage in August," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "We are now more than halfway to our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end. As we enter fiscal 2027, we expect the momentum we built in the fourth quarter to carry forward, with growing institutional demand, deeper penetration into academic and community treatment centers, and continued sales growth as LYMPHIR becomes further established in CTCL."
Preliminary Fiscal Fourth Quarter 2026 Highlights (unaudited)
- 792 units purchased by
U.S . wholesalers for the three months ended September 30, 2026, compared to 360 units for the three months ended June 30, 2026, an increase of120% ; - 950 LYMPHIR vials ordered by prescribing centers from wholesalers during the fiscal fourth quarter, compared to 926 for the fiscal third quarter; and
- As of the date of this release, 54 institutions have now ordered LYMPHIR, compared to 44 as of August 14, 2026, as last reported.
The unit information in this release is preliminary and unaudited, is based on management's current estimates, and is subject to completion of the Company's year-end closing procedures and the audit of its fiscal 2026 financial statements. Actual results may differ, and the Company's independent registered public accounting firm has not audited, reviewed or performed any procedures on these preliminary figures. The Company recognizes revenue when wholesaler orders are fulfilled. Accordingly, the Company's revenue is based on LYMPHIR units sold to wholesalers, net of estimated gross-to-net adjustments, rather than on institutional vial orders from wholesalers by institutions. Citius Oncology expects to report complete fiscal fourth quarter and fiscal year 2026 results in December 2026 with the filing of its Annual Report on Form 10-K.
About LYMPHIR® (denileukin diftitox-cxdl)
LYMPHIR is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I–III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing DT fragments that have entered cells to inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl has demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors. LYMPHIR was approved by the FDA and subsequently launched in the
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma is the majority owner of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the possibility that the preliminary, unaudited unit information in this press release may differ from our final results upon completion of year-end closing procedures and the audit of our financial statements; quarterly shipments may fluctuate based on wholesaler purchasing patterns and inventory levels; we may not achieve our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq's continued listing standards; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain, perform under, and maintain third-party agreements and relationships, including obtaining a new bulk drug substance supplier; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; risks relating to the results of research and development activities; our ability to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings, which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Contacts
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact: STiR-communications
Greg Salsburg
greg@stir-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-reports-continued-institutional-demand-and-120-growth-in-shipments-of-lymphir-units-to-us-wholesalers-during-the-fiscal-fourth-quarter-of-2026-302919586.html
SOURCE Citius Oncology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Citius Oncology's LYMPHIR wholesaler sales grow in fiscal Q4 2026?
Preliminary LYMPHIR unit sales to U.S. wholesalers rose 120%, reaching 792 units in the three months ended September 30, 2026, compared with 360 in the three months ended June 30, 2026. These figures are unaudited.
How does Citius Oncology recognize LYMPHIR revenue?
Citius Oncology recognizes revenue when wholesaler orders are fulfilled, net of estimated gross-to-net adjustments. Revenue is based on units sold to wholesalers, rather than vial orders placed by institutions with wholesalers.